KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Liabilities (2023 - 2025)

Biocryst Pharmaceuticals' Total Liabilities history spans 9 years, with the latest figure at $633.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 34.46% year-over-year to $633.3 million; the TTM value through Dec 2025 reached $633.3 million, down 34.46%, while the annual FY2025 figure was $633.3 million, 34.46% down from the prior year.
  • Total Liabilities reached $633.3 million in Q4 2025 per BCRX's latest filing, down from $834.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $972.5 million in Q4 2023 to a low of $633.3 million in Q4 2025.
  • Average Total Liabilities over 3 years is $896.6 million, with a median of $932.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: increased 12.65% in 2024, then crashed 34.46% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $972.5 million in 2023, then fell by 0.63% to $966.4 million in 2024, then plummeted by 34.46% to $633.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Total Liabilities are $633.3 million (Q4 2025), $834.3 million (Q3 2025), and $878.8 million (Q2 2025).